The promise and challenges of targeting RSK for the treatment of cancer

Expert Opinion on Therapeutic Targets

Volumn 15, Issue 1, 2011, Pages 1-4

  Stratford, Anna L ^a   Dunn, Sandra E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONYL TRIFLUOROMETHYL KETONE; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; BID 1870; CONNECTIVE TISSUE GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PROTEIN KINASE INHIBITOR; RIBOSOMAL S6 KINASE; S6 KINASE; SL 0101; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

CANCER CELL CULTURE; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; DRUG INHIBITION; DRUG SAFETY; DRUG TARGETING; HEAD AND NECK CANCER; HUMAN; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SUPPRESSOR GENE; T CELL LYMPHOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA;

EID: 78650206189     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2011.537656     Document Type: Review

References (30)

1. Smith JA, Poteet-Smith CE, Xu Y, et al. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 2005;65:1027-34
2. Clark DE, Errington TM, Smith JA, et al. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res 2005;65:3108-16
3. Cuadrado A, Nebreda AR. New insights into RSK activation and hematopoietic cancer. Cancer Cell 2007;12:187-9
4. Kang S, Dong S, Gu TL, et al. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 2007;12:201-14
5. Kang S, Elf S, Dong S, et al. Fibroblast growth factor receptor 3 associates with amd tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation. Mol Cell Biol 2009;29:2105-17
6. Mirmohammadsadegh A, Mota R, Gustrau A, et al. ERK 1/2 is highly phosphorylated in melanoma metastases and protects melanoma cells from cisplatin-mediated apoptosis. J Invest Dermatol 2007;127:2207-15
7. Kang S, Elf S, Lythgoe K, et al. p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells. J Clin Invest 2010;120:1165-77
8. Cho Y-Y, Yao K, Kim H-G, et al. Ribosomal S6 kinase 2 is a key regulator in tumor promoter-induced cell transformation. Cancer Res 2007;67:8104-12
9. Xian W, Pappas L, Pandya D, et al. Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Res 2009;69:2244-51
10. Bignone PA, Lee KY, Liu Y, et al. RPS6KA2, a putative tumor suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene 2007;26:683-700
11. Thakur A, Sun Y, Bollig A, et al. Anti-invasive and antimetastatic activities of ribosomal S6 kinase 4 in breast cancer cells. Clin Cancer Res 2008;14:4427-36
12. Kang S, Chen J. Targeting RSK2 in human malignancies. Expert Opin Ther Targets 2011;15:11-20
13. Astanehe A, Finkbeiner MR, Hojabrpour P, et al. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. Oncogene 2009;28:2406-18
14. Anjum R, Blenis J. The RSK family of kinases: Emerging roles in cellular signalling. Nat Rev Mol Cell Biol 2008;9:747-58
15. Stratford AL, Fry CJ, Desilets C, et al. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res 2008;10(6):R99
16. Dhillon J, Astanehe A, Lee C, et al. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells. Oncogene 2010: Published online 30 August 2010, doi:10.1038/ onc.2010.365
17. Clark DE, Poteet-Smith CE, Smith JA, Lannigan DA. Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain. EMBO J 2001;20:3484-94
18. Zoubeidi A, Zardan A, Wiedmann RM, et al. Hsp27 promotes insulin-like growth factor-1 survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res 2010;70:2307-17
19. Moritz A, Li Y, Guo A, et al. Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases. Sci Signal 2010;3:ra64
20. Law JH, Habibi G, Hu K, et al. Phosphorylated insulin-like growth factor-1/insulin receptor is present in all breast cancersubtypes and is related to poor survival. Cancer Res 2008;68:10238-46
21. Harris LN, You F, Schnitt SJ, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007;13:1198-207
22. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: A further update. Biochem J 2007;408:297-315
23. Malakhova M, Kurinov I, Liu K, et al. Structural diversity of the active N-terminal kinase domain of p90 ribosomal S6 kinase 2. PLoS One 2009;4:e8044
24. Sapkota GP, Cummings L, Newell FS, et al. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. J Biochem 2007;401:29-38
25. Law JH, Li Y, To K, et al. Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability. PLoS One 2010;5:e12661
26. Dufresne SD, Bjorbæk C, El-Haschimi K, et al. Altered extracellular signal-regulated kinase signaling and glycogen metabolism in skeletal muscle from p90 ribosomal S6 kinase 2 knockout mice. Mol Cell Biol 2001;21:81-7
27. El-Haschimi K, Dufresne SD, Hirshman MF, et al. Insulin resistance and lipodystrophy in mice lacking ribosomal S6 kinase 2. Diabetes 2003;52:1340-6
28. Lin JX, Spolski R, Leonard WJ. Critical role for Rsk2 in T-lymphocyte activation. Blood 2008;111:525-33
29. Stevenson MA, Zhao M, Asea A, et al. Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcription of cyclin AMP response element binding protein and NF-kappaB response genes. J Immunol 1999;163:5608-16
30. Cohen MS, Hadjivassiliou H, Taunton J. A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Nat Chem Biol 2007;3:156-60